Highest-materiality recent filing
Balchem Q1 net sales $270.7M (+8.1%); adjusted EBITDA $74.3M (+12.1%)
Net sales $270.7M, up 8.1% YoY; GAAP EPS $1.25, adjusted EPS $1.33.
Q4 net sales $263.6M (+9.8% YoY); GAAP EPS $1.21 vs $1.03; adjusted EPS $1.31 vs $1.13.
Balchem appoints Erin L. Gilson as CAO effective April 1, 2026
William A. Backus, VP and Chief Accounting Officer, retiring on March 31, 2026.
Balchem declares $0.96 annual dividend (10.3% increase), authorizes repurchase of up to 4M shares
Dividend of $0.96 per share declared on Dec 9, 2025, payable Jan 20, 2026 to holders of record Dec 23, 2025.
Balchem Q3 2025: record sales $267.6M, adj. EPS $1.35, all segments grow
Record net sales $267.6M (+11.5% YoY); GAAP EPS $1.24 vs $1.03; adjusted EPS $1.35 vs $1.13.
Balchem Q2 2025: record net sales $255.5M, adj. EPS $1.27 beat
Net sales $255.5M, +9.1% YoY; GAAP EPS $1.17 vs $0.98 prior year quarter.
Balchem shareholders elect three Class 1 directors, ratify auditor, approve say-on-pay
Theodore L. Harris elected with 24.96M votes for; 1.26M against; 963k abstain; 2.20M broker non-votes.
Balchem Q1 net sales $250.5M record; adj. EPS $1.22 vs $1.03 YoY; all segments grow
Net sales of $250.5M, up 4.5% YoY; GAAP EPS $1.13 vs $0.89; adjusted EPS $1.22 vs $1.03.
Balchem CAO William A. Backus to retire on March 31, 2026; successor not yet named
William A. Backus, Vice President and Chief Accounting Officer, notified of retirement effective March 31, 2026.
Balchem Q4 record net sales $240M, adjusted EBITDA $62.8M, EPS $1.03
Q4 net sales record $240.0M (+4.9% YoY); GAAP EPS $1.03 vs $0.82; adjusted EPS $1.13 vs $0.95.
Balchem adopts executive severance policy and enhances deferred comp match for officers
New Executive Severance Policy provides cash severance (multiple of salary plus target bonus) and COBRA for termination without Cause or Involuntary Termination within Change in Control (CIC) Period.
Balchem declares $0.87 dividend, 10.1% increase; payable Jan 17, 2025
Quarterly dividend set at $0.87 per share, a 10.1% increase versus prior year.
Balchem Q3 net sales up 4.3% to $239.9M; record adjusted EBITDA $64.4M, up 7.6% YoY
GAAP EPS $1.03 versus $0.90 prior year; adjusted EPS record $1.13 versus $1.04.
Joyce Lee resigns from Balchem board following planned employment change
Joyce Lee resigned as director on Oct 16, 2024, due to planned change in principal employment.
Directors Knutson, Lee, Vicente, and Fish moved among Class 1, 2, and 3 to approximate one-third per class, effective Sept 20, 2024.
Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)
GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.
Balchem shareholders elect four Class 2 directors and ratify RSM US LLP as auditor
Daniel Knutson, Joyce Lee, Olivier Rigaud, Monica Vicente elected as Class 2 directors (2027 term).
Balchem reports record Q1 net sales of $239.7M, adjusted EBITDA up 8%
Net sales $239.7M (+3.1% YoY), adjusted EBITDA $60.9M (+8.0% YoY), both all-time records.
William A. Backus, Vice President and Chief Accounting Officer, has notified the Company of his intent to retire from his position on March 31, 2026.
On October 16, 2024, the Corporate Governance and Nominating Committee of the Balchem Corporation (“Balchem”) Board of Directors (the “Board”) accepted the resignation of Joyce Lee as a Director.
Max materiality 0.75 · Median 0.65 · Most common event earnings